Updated: November 19, 2025
Rani Therapeutics Holdings (NASDAQ: RANI) finished Wednesday, Nov. 19, 2025 at $1.75, down from $1.86 on Tuesday. The stock opened at $1.83, traded between $1.70–$1.90, and moved ~2.5M shares on the day, according to end‑of‑day pricing data.
Today’s trading at a glance (19.11.2025)
- Close: $1.75 (vs. $1.86 prior close) → ‑5.9% day‑over‑day based on Yahoo’s daily summary.
Range: $1.70–$1.90. Open: $1.83. Volume: ~2,507,020. - Sector tone: Biotech benchmarks were broadly steady; the SPDR S&P Biotech ETF (XBI) closed at 114.81 on Nov. 19 vs. 113.93 on Nov. 18.
Was there fresh company news today?
As of publication on Nov. 19, no new Rani press releases or material company updates were posted today. The most recent company news remains the Q3 2025 results issued Nov. 6.
Likewise, no new SEC filings were posted today; the latest notable filing was a Schedule 13G amendment filed on Nov. 14, 2025.
Quick background: why RANI has been on watch
- Chugai partnership (headline driver in October): On Oct. 17, Rani unveiled a collaboration and license deal with Chugai that could reach up to $1.09B across multiple programs (initial $10M upfront, potential tech‑transfer and sales milestones, and single‑digit royalties on the first program). Shares spiked on the news.
- Balance sheet & runway: In its Q3 2025 update, Rani said it closed a $60.3M private placement and expects cash runway into 2028, bolstering development plans.
- What’s next in the clinic: Management reiterated plans to initiate a Phase 1 trial of RT‑114 (oral GLP‑1/GLP‑2 for obesity) by year‑end 2025, and highlighted preclinical data showing that semaglutide delivered via the RaniPill® capsule achieved comparable exposure and weight‑loss effects to subcutaneous dosing (presented at ObesityWeek 2025).
Interpreting today’s move
With no fresh headlines on Nov. 19, today’s slide likely reflects positioning after October’s sharp re‑rating and trader focus on near‑term milestones (notably the RT‑114 first‑in‑human start). The broader biotech tape was modestly positive on the day (XBI higher vs. Tuesday), suggesting stock‑specific consolidation rather than a sector‑wide risk‑off day.
What to watch from here
- RT‑114 Phase 1 start (EOY 2025): Confirmation of first‑patient‑in and initial safety readouts will be the next material catalyst for the obesity program.
- Execution on the Chugai collaboration: Any disclosure on the first rare‑disease program’s progress, optioning of additional targets, or technology‑transfer milestones could move the stock.
- Capital structure and filings: The October financing added cash and included warrants; keep an eye on ownership disclosures (e.g., recent Armistice Capital 13G in mid‑November) and any subsequent SEC filings.
- Listing‑compliance checkpoints: Earlier in 2025, Rani disclosed Nasdaq notices tied to market‑value and minimum bid requirements; one notice referenced a Dec. 17, 2025 remedy window for the $1.00 bid price rule. Investors will watch for formal updates on compliance status.
Analyst snapshot (context, not advice)
Coverage remains generally constructive: MarketBeat aggregates a “Moderate Buy” consensus across 5 analysts over the past year. Some other aggregators rate it more strongly, but methodologies and coverage sets differ. Always read the underlying notes before relying on any consensus. MarketBeat
Key facts for 19.11.2025 (recap)
- Ticker: RANI (Nasdaq)
- Close:$1.75 (from $1.86 on Nov. 18)
- Day’s range:$1.70–$1.90; Open:$1.83; Volume:~2.51M.
- Most recent company news:Q3 results (Nov. 6); no new press release filed today.
- Recent strategic headline:Up to $1.09B Chugai collaboration (Oct. 17).
Bottom line
On Nov. 19, 2025, RANI fell ~6% to $1.75 without new company‑specific headlines. The stock remains event‑driven into year‑end as investors look for RT‑114’s Phase 1 start and continued execution on the Chugai partnership—two levers that could reshape sentiment and the medium‑term story.
This article is for information only and is not investment advice. Always do your own research and consider consulting a licensed financial advisor before making investment decisions.
